Close Navigation
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
OverlayOverlay
Artios logo

Find out more →

OverlayOverlay
Autolus logo

Find out more →

OverlayOverlay
LogicBio logo

Find out more →

INVESTING IN LIFE CHANGING SCIENCE

Discover more

Our Portfolio

Unconstrained by institution, geography or stage of company development; we have the ability to source the best life science innovation without restriction. We partner with the most ambitious entrepreneurs to build companies around game changing life science innovation.

View full portfolio
Video
Video
Takeda

Takeda is a global, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing better health and a brighter future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases.

UCB

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology or neurology. UCB is listed on Euronext Brussels (symbol: UCB).

Fosun

Fosun is a multinational company that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007. Fosun's mission is to create Customer-to-Maker ecosystems in health, happiness and wealth, providing high-quality products and services for families around the world.

Ipsen

Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The group develops and commercialises innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases.

Max Planck LDC

The Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalise on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC seeks to advance promising research projects into the development of novel medicines

Takeda

UCB

Fosun

Ipsen

Max Planck LDC

Partners

Arix has developed a wide network that includes pharma companies, research accelerators and universities. Through this network, Arix is able to identify new technologies and discoveries that provide a rich pipeline of potential investments.

Team

Experienced and collaborative team, with deep industry and scientific expertise.

Meet the team
Mesh

Investors

Public market access to revolutionary medical innovation.

Find the latest share price, presentations, events and regulatory announcements here.

Visit Investor Centre
Share price

Latest News

Updates from Arix and our porfolio companies.

Read more news

Portfolio Company

15th July 2021

Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer

Portfolio Company

13th July 2021

Imara Announces Pricing of Public Offering

Portfolio Company

13th July 2021

Imara Announces Launch of Proposed Public Offering

Portfolio Company

8th July 2021

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021